Want to see IN:NGLFINE full AI Analyst Report?
NGLFINE Stock Chart & Stats
₹3194.85
₹21.00(0.66%)
At close: 4:00 PM EDT
₹3194.85
₹21.00(0.66%)
Day’s Range― - ―
52-Week Range₹1,261.00 - ₹3,595.00
Previous CloseN/A
Volume7.53K
Average Volume (3M)156.00
Market Cap
₹17.93B
Enterprise Value₹13.58K
Total Cash (Recent Filing)₹442.99M
Total Debt (Recent Filing)₹1.09B
Price to Earnings (P/E)31.3
Beta1.00
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.06%
Share Statistics
EPS (TTM)77.77
Shares Outstanding6,178,024
10 Day Avg. Volume192
30 Day Avg. Volume156
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)3.86
Price to Sales (P/S)2.54
P/FCF Ratio-25.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Rebound & Margin RecoveryA 22.6% revenue rebound alongside net margin improvement to ~9.6% reflects recovering demand and reinstated operational leverage. Sustained top-line momentum with margin recovery supports durable earnings capacity, funds reinvestment, and reduces execution risk over the medium term.
Manageable Leverage And Improving ROEDebt levels have risen but remain moderate and equity has grown, offering balance-sheet capacity for investment. ROE doubling to ~14.6% indicates capital is becoming more productive, supporting sustainable returns while preserving financing flexibility if leverage is managed prudently.
Consistent Operating Cash GenerationPositive operating cash flow in each reported year shows the core business generates cash even when free cash flow is negative. This recurring cash from operations provides a base to fund working capital and capex and reduces absolute reliance on external financing over time.
Bears Say
Persistent Negative Free Cash FlowRepeated negative free cash flow erodes financial flexibility and forces reliance on external funding or asset sales to cover investments. Over months to years this constrains dividends, buybacks and deleveraging, and raises vulnerability to higher interest rates or funding-market stress.
Material Gross-margin CompressionA roughly 15 percentage-point drop in gross margin meaningfully lowers profit per unit sold and tightens operating margin headroom. Structural margin pressure reduces resilience to cost inflation and demands sustained pricing power, efficiency gains, or a shift to higher-margin products to restore profitability.
Rising Leverage TrendWhile current leverage is moderate, the rapid increase in debt-to-equity over three years signals rising financial risk if earnings weaken. Continued debt growth could elevate interest burdens, reduce strategic optionality and increase sensitivity to cyclical earnings swings over the medium term.
NGL Fine-Chem Ltd. News
NGLFINE FAQ
What was NGL Fine-Chem Ltd.’s price range in the past 12 months?
NGL Fine-Chem Ltd. lowest stock price was ₹1261.00 and its highest was ₹3595.00 in the past 12 months.
What is NGL Fine-Chem Ltd.’s market cap?
NGL Fine-Chem Ltd.’s market cap is ₹17.93B.
When is NGL Fine-Chem Ltd.’s upcoming earnings report date?
NGL Fine-Chem Ltd.’s upcoming earnings report date is Nov 06, 2026 which is in 70 days.
How were NGL Fine-Chem Ltd.’s earnings last quarter?
NGL Fine-Chem Ltd. released its earnings results on Aug 12, 2026. The company reported ₹29.778 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is NGL Fine-Chem Ltd. overvalued?
According to Wall Street analysts NGL Fine-Chem Ltd.’s price is currently Overvalued.
Does NGL Fine-Chem Ltd. pay dividends?
NGL Fine-Chem Ltd. pays a Annually dividend of ₹1.75 which represents an annual dividend yield of 0.06%. See more information on NGL Fine-Chem Ltd. dividends here
What is NGL Fine-Chem Ltd.’s EPS estimate?
NGL Fine-Chem Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NGL Fine-Chem Ltd. have?
NGL Fine-Chem Ltd. has 6,178,024 shares outstanding.
What happened to NGL Fine-Chem Ltd.’s price movement after its last earnings report?
NGL Fine-Chem Ltd. reported an EPS of ₹29.778 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.376%.
Which hedge fund is a major shareholder of NGL Fine-Chem Ltd.?
Currently, no hedge funds are holding shares in IN:NGLFINE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NGL Fine-Chem Ltd.
Headquartered in Mumbai, India, and established in 1981, NGL Fine-Chem Limited operates as a worldwide producer and distributor of pharmaceutical ingredients and intermediates for both veterinary and human health sectors. The company's comprehensive portfolio of active pharmaceutical ingredients (APIs) for animal applications features substances like diminazene aceturate, diminazene diaceturate, homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, ractopamine HCl, S-methoprene, praziquantel, toltrazuril, decoquinate, flunixin meglumine, carprofen, fenbendazole, amitraz, and marbofloxacin. For human therapeutic use, they supply APIs including nitazoxanide, atovaquone, and ranolazine. Furthermore, NGL Fine-Chem manufactures various intermediate compounds and offers completed pharmaceutical formulations in both granule and tablet formats.
Technical Analysis
Gland Pharma Ltd.
―
Kopran Limited
―
Marksans Pharma Limited
―
SMS Pharmaceuticals Limited
―
Senores Pharmaceuticals Ltd.
―